Ryoichi Ishibashi

20PUBLICATIONS
34CO-AUTHORS
Optical technologyMolecular targetsPharmacogenomicsGene and molecular therapyTraditional Chinese medicine and treatments
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (20)

|Sep 10, 2026
Renal Safety of Intravitreal Ranibizumab and the Effects of SGLT2 Inhibition in Diabetic Macular Oedema: A Post Hoc Analysis of the COMET Trial.

|Sep 02, 2026
Sodium-Glucose Cotransporter 2 Inhibition in Diabetic Macular Oedema: Emerging Evidence for Stage-Dependent Systemic-Retinal Responsiveness.

|Aug 12, 2026
Association of GLP-1 Receptor Agonist Use With Cardiovascular Outcomes and Mortality in Japanese Patients With Type 2 Diabetes: A Real-World Claims Database Study.

|Aug 04, 2025
Sodium-glucose co-transporter 2 inhibitors reduce the intravitreal anti-VEGF treatment necessity in eyes with early diabetic macular oedema: A post-hoc analysis focusing on the fellow eye of the COMET trial.

Tomoaki Tatsumi, Yoko Takatsuna, Ryoichi Ishibashi

|Feb 12, 2025
Ranibizumab with luseogliflozin in type 2 diabetes with diabetic macular oedema: A randomised clinical trial.

Ryoichi Ishibashi, Yoko Takatsuna, Masaya Koshizaka

|Jan 14, 2025
Effects of the SGLT2 inhibitor ipragliflozin and metformin on hepatic steatosis and liver fibrosis: Sub-analysis of a randomized controlled study.

Kiichi Hirayama, Masaya Koshizaka, Ryoichi Ishibashi

Pageof 4

Frequent Collaborators

13 joint publications

Masaya Koshizaka

12 joint publications

Koutaro Yokote

3 joint publications

Kiichi Hirayama

2 joint publications

Kengo Nagashima